The 15 billion contrast agent market welcomes new players again!

According to data from Menet.
com, in 2020, the sales of terminal contrast agents in public medical institutions in China will exceed 15 billion yuan, with a year-on-year growth of more than 25% in 2021H1
.
From the perspective of manufacturers, Jiangsu Hengrui Pharmaceutical, General Electric, Yangtze River Pharmaceutical Group, Bayer, and Bracco rank in the top five; among the TOP10 products, three of them have sales of more than 1 billion yuan; among the TOP10 brands, Hengrui Pharmaceuticals and General Motors Four companies including Electric and Yangtze River Pharmaceutical Group each have two brands on the list.
The iodixanol injection of Nanjing Chia Tai Tianqing Pharmaceutical has the fastest growth rate, reaching 194.
16%
.
Since 2018, a total of 13 contrast agents are under review.
Among them, no domestic generic drug companies such as iopromide injection and gadoterol injection have been approved, involving Jiangsu Hengrui Pharmaceuticals, Chengdu Better Pharmaceuticals, and Hunan Kelun Pharmaceutical, Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical and many other companies
.
The 15 billion contrast agent market is making waves again! Three products have been approved this year.
Sales of terminal contrast agents in China's public medical institutions in recent years (unit: 100 million yuan) Source: Mynet.
com China's public medical institutions' terminal competition pattern.
Recently, the 2021 national medical insurance drug catalog adjustment that has received much attention has fallen.
Under the curtain, two contrast media products, perfluorobutane microspheres for injection and perfluoropropane human albumin microspheres for injection, were included in the medical insurance list through negotiation
.
Not long ago, Chia Tai Tianqing Pharmaceutical Group's gadoxetate disodium injection was approved as a supplementary application and became the second company to pass the evaluation
.
In addition, with the implementation of the fifth batch of centralized procurement, the two winning bids of iohexol injection and iodixanol injection will make waves again
.
According to data from Menet.
com, the sales of terminal contrast agents in China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) rose from less than 10 billion yuan in 2016 to more than 15 billion yuan in 2019.
There will be a slight decline in 2020, with a year-on-year growth of more than 25% in 2021H1
.
From the perspective of manufacturers, Jiangsu Hengrui Pharmaceutical, General Electric, Yangtze River Pharmaceutical Group, Bayer, and Bracco are in the top five, with a total market share of more than 80%; Nanjing Zhengda Tianqing Pharmaceutical has a strong growth rate of more than 200% Rise to the eighth place, the fastest growing manufacturer in the TOP10
.
Contrast agent products approved for marketing since 2021.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database.
Since this year, 3 contrast agents have been approved for marketing, namely Nanjing Hairong Pharmaceutical | Nanjing Hairong Pharmaceutical Technology's Regano Shengsheng injection, Shandong Kelun Pharmaceutical's iopamidol injection, Hunan Kelun Pharmaceutical's Gadoxetate Disodium Injection
.
Reganosant injection is the world's first selective adenosine A2a receptor agonist.
It dilates coronary arteries by selectively activating adenosine A2a receptors and increases coronary blood flow for use as MPI-loading drugs, with selective expansion Coronary artery, rapid onset of action, fixed dose administration and other characteristics
.
Reganosun injection was approved by the US FDA in April 2008, and the original research has not been marketed in China
.
In October of this year, Nanjing Hairong Pharmaceutical|Nanjing Hairong Pharmaceutical Technology won the first imitation, which is also the company's second domestically listed generic pharmaceutical product
.
It is worth mentioning that this product is the national "Major New Drug Creation" 13th Five-Year Science and Technology Major Special Project Supported Product, filling the gap in the diagnosis and medication of myocardial perfusion imaging in China
.
Iopamidol nonionic monomers Italy Bracco contrast agents developed for neuroradiological related, angiography, digital subtraction angiography, urography, CT scanning enhanced examination
.
In June of this year, Kelun issued an announcement stating that its subsidiary Shandong Kelun Pharmaceutical's iopamidol injection was approved for marketing.
This product is Kelun's first drug approved to enter the field of diagnostic imaging
.
In September, Hunan Kelun Pharmaceutical's Gadoxetate Disodium Injection was approved for marketing.
This is the second contrast agent approved by Kelun, and it is also the second domestically produced company for the product
.
TOP10 products have surged across the board, with sales of three major products exceeding 1 billion.
2021H1 China's public medical institutions' terminal contrast agent products TOP10 Source: Minet.
com China's public medical institutions' terminal competition pattern Among the TOP10 products, three products have sales of more than 1 billion yuan
.
Iodixanol injection ranked first with sales of more than 2 billion yuan, followed by iohexol injection and ioverol injection, ranking second and third.

.
From the perspective of growth rate, 10 products have exceeded double-digit growth.
Among them, iomeprol injection has a surprising increase of 196.
05%, making it into the top ten; sulphur hexafluoride microbubbles for injection and iodixanol injection Soaring more than 40%
.
2021H1 Top 10 Chinese Public Medical Institutions' Terminal Contrast Media Brands Source: Menet.
com.
Chinese Public Medical Institutions' Terminal Competitive Pattern.
Among the TOP10 brands, two brands have sales of more than 1 billion yuan
.
Four companies including Hengrui Pharmaceutical, General Electric, and Yangtze River Pharmaceutical Group each have two brands on the list
.
In terms of growth rate, Nanjing Chia Tai Tianqing Pharmaceutical's iodixanol injection is the fastest, with sales soaring from more than 20 million yuan in 2019 to more than 200 million yuan in 2020, and a year-on-year growth of 194.
16% in 2021H1
.
13 contrast agents are under review! Yangtze River, Kelun, Beite.
.
.
the first to review the situation of imitation contrast agents.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database Up to now, 7 contrast agent products have been reviewed by enterprises.
Among them, iohexol injection And iodixanol injection has been included in the fifth batch of centralized procurement, iopamidol injection and gadoxetate disodium injection have met the competition conditions of 3 or more (3 over-rated or 2 over-rated +1 Home original research)
.
In addition, there are three supplementary applications for consistency evaluation of products under review and approval, namely Fuan Pharmaceutical Group Ningbo Tianheng Pharmaceutical’s Iohexol Injection, Jiangsu Hengrui Pharmaceutical’s Gadoterate Meglumine Injection, and Beijing Beilu Pharmaceutical's iopamidol injection
.
Contrast agent production under review since 2018.
Source: Meinenet MED2.
0 China Drug Evaluation Database.
Since 2018, a total of 13 contrast agents are under review and approval.
Among them, gadobutrol injection is the most popular, with 4 Companies; 5 products including iopamidol injection, gadoterate meglumine injection, and poppy iodized oil injection have been submitted for production by 2 companies
.
In addition, iopromide injection, gadobutrol injection, gadobutrol injection and other domestic generic pharmaceutical companies have not been approved, involving Jiangsu Hengrui Pharmaceutical, Chengdu Better Pharmaceutical, Hunan Kelun Pharmaceutical, Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceutical and many other companies
.
Source: Mi Nei.
com database, company announcements.
Statistics are as of December 6.
If there are any omissions, please correct me!